IceCure Medical Ltd (NASDAQ:ICCM – Free Report) – Brookline Capital Management raised their FY2023 earnings per share (EPS) estimates for IceCure Medical in a research note issued on Wednesday, November 15th. Brookline Capital Management analyst K. Dolliver now expects that the company will earn ($0.34) per share for the year, up from their previous estimate of ($0.37). The consensus estimate for IceCure Medical’s current full-year earnings is ($0.36) per share. Brookline Capital Management also issued estimates for IceCure Medical’s FY2024 earnings at ($0.42) EPS and FY2025 earnings at ($0.23) EPS.
Several other research analysts have also recently issued reports on ICCM. HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of IceCure Medical in a research note on Wednesday, September 6th. Alliance Global Partners decreased their price target on IceCure Medical from $4.25 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, August 15th.
IceCure Medical Trading Up 2.7 %
NASDAQ:ICCM opened at $0.74 on Monday. IceCure Medical has a 1 year low of $0.52 and a 1 year high of $4.73. The stock has a market cap of $33.76 million, a price-to-earnings ratio of -2.00 and a beta of 0.23. The business has a fifty day moving average of $0.82 and a 200-day moving average of $1.03. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.59 and a current ratio of 5.30.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Bank of America Corp DE boosted its stake in IceCure Medical by 57.2% during the fourth quarter. Bank of America Corp DE now owns 55,388 shares of the company’s stock valued at $86,000 after buying an additional 20,159 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in shares of IceCure Medical in the 2nd quarter valued at $78,000. Boothbay Fund Management LLC boosted its position in shares of IceCure Medical by 100.0% in the 4th quarter. Boothbay Fund Management LLC now owns 40,000 shares of the company’s stock valued at $62,000 after purchasing an additional 20,000 shares during the period. Finally, UBS Group AG boosted its position in shares of IceCure Medical by 1,302.3% in the 4th quarter. UBS Group AG now owns 28,986 shares of the company’s stock valued at $45,000 after purchasing an additional 26,919 shares during the period. Institutional investors own 0.34% of the company’s stock.
IceCure Medical Company Profile
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
- Five stocks we like better than IceCure Medical
- How to Calculate Retirement Income: MarketBeat’s Calculator
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Are Penny Stocks a Good Fit for Your Portfolio?
- MarketBeat Week in Review – 11/13 – 11/17
- Trading Stocks: RSI and Why it’s Useful
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.